A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

Phase 1

Completed

Brief Summary: This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Recruitment & Eligibility

Inclusion Criteria

Overtly healthy male or a female who cannot get pregnant
Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m²), inclusive, at screening
Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
Have veins suitable for ease of blood sampling

Exclusion Criteria

Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
Have previously completed or withdrawn from this study
Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking during the inpatient stay in the study
Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
Have been treated with weight loss medications within 3 months of screening

Arm && Interventions

Group	Intervention	Description
Placebo - SC	Placebo - SC	Participants received Placebo subcutaneously (SC).
0.15 mg LY3493269 SC	LY3493269 - SC	Participants received 0.15 mg LY3493269 SC.
1.5 mg LY3493269 SC	LY3493269 - SC	Participants received 1.5 mg LY3493269 SC.
0.5 mg LY3493269 IV	LY3493269 - IV	Participants received 0.5 mg LY3493269 intravenously (IV).
0.5 mg LY3493269 SC	LY3493269 - SC	Participants received 0.5 mg LY3493269 SC.

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Baseline through final follow-up (Up To Day 43)	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Infinity (AUC 0-∞) of LY3493269	Day 1: Predose, 6, 12 hours; Day 2: 24 hours; Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6:120 hours; Day 8:168 hours; and any time during the visit on Day 15, Day 29, Day 43 and early termination	Pharmacokinetics (PK): Area Under the Concentration time curve from time zero to infinity (AUC 0-∞) of LY3493269
PK: Maximum Concentration (Cmax) of LY3493269	Day 1: Predose, 6, 12 hours; Day 2: 24 hours; Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6:120 hours; Day 8:168 hours; and any time during the visit on Day 15, Day 29, Day 43 early termination	PK: Maximum Concentration (Cmax) of LY3493269
PK: Time to Maximum Concentration (Tmax) of LY3493269	Day 1: Predose, 6, 12 hours; Day 2: 24 hours; Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6:120 hours; Day 8:168 hours; and any time during the visit on Day 15, Day 29, Day 43 early termination	PK: Time to Maximum Concentration (Tmax) of LY3493269